FDA Extends Review Period for Capricor Therapeutics' Deramiocel BLA

The U.S. Food and Drug Administration (FDA) has extended the PDUFA target action date for Capricor Therapeutics' Biologics License Application (BLA) for deramiocel to November 22. This extension allows the FDA more time to complete its review of the drug.